China Resources Pharmaceutical's mid -2022 net profit increased by 26.2% year -on -year

On August 25, 2022, China Resources Pharmaceutical (03320.HK), a Hong Kong stock market company, announced its mid -term performance in 2022.

In the middle of 2022, the company's total income reached HK $ 125.717 billion, a year -on -year increase of 9.8%. In the first half of 2022, the proportion of the three main business branches of pharmaceutical, pharmaceutical distribution, and pharmaceutical retail sales accounted for 16.0%, 80.8%, and 3.2%, respectively.

During the reporting period, the company realized a gross profit Hong Kong dollars of 19.832 billion yuan, an increase of 13.6%year -on -year; the overall gross profit margin was 15.8%, an increase of 0.5 percentage points compared with 15.3%in the first half of 2021, mainly because the gross profit margin level was high during the reporting period. The proportion of pharmaceutical business revenue increased; net profit was HK $ 5.168 billion, an increase of 26.2%year -on -year; the company's owners accounted for 3.025 billion yuan, an increase of 24.1%year -on -year; the basic profit per share was HK $ 0.48.

During the period, the yield of the pharmaceutical business realized HK $ 22.177 billion, an increase of 18.0%year -on -year. CHC (mainly includes non -prescription drugs and health products), prescription drugs and biopharmaceutical sectors generally achieved year -on -year growth. The gross profit margin of the pharmaceutical business was 58.2%, a decrease of 1.1 percentage points from the gross profit margin level in the same period of the previous year, mainly due to the joint influence of the volume procurement and product structure changes.

The Chinese medicine business recorded the income of HK $ 10.375 billion in the recording of the Chinese medicine business of the pharmaceutical business sector, an increase of 9.4%over the same period of the previous year, of which: the income of traditional Chinese medicine non -prescription drug business increased by 9.9%year -on -year, mainly due to the revenue of Ejiao series products, gastrointestinal, pediatrics and orthopedics, and achieved stableness year -on -year. Growth; Chinese medicine prescription drug business income increased by 7.5%year -on -year, mainly due to the growth of Chinese medicine drinks and Chinese medicinal materials business income. HK $ 9.187 billion in the recording of the chemical drug business, an increase of 15.4%over the same period of the previous year, of which: the income of the non -prescription drug business of chemical drugs increased by 14.5%year -on -year, mainly benefiting from the increase in the income of gastrointestinal, skin, pediatrics, and reproductive health; Business revenue increased by 17.1%year -on -year, mainly due to the increase in business income in the fields of cardiovascular and cerebrovascular, large infusion, anti -infection, and sugar hypoglycemic; the income of raw and drug business increased by 5.0%year -on -year.

The biopharmaceutical business achieved HK $ 1.596 billion in revenue, an increase of 1,545.0%from the same period last year. It mainly benefited from the company's mergers and acquisitions of China Resources Boya Bio and Jincheng Hais Pharmaceutical Co., Ltd. in the previous year.

In the first half of 2022, the company's total R & D total expenditure was about HK $ 1.05 billion, a significant increase of 34.5%year -on -year. As of June 39, 2022, the company's new product development was developed in nearly 300 research projects, of which nearly 100 new drug projects were mainly involved in tumor and immunity, metabolism and endocrine, respiratory, blood, cardiovascular, Chinese medicine classic famous prescriptions, etc. field.

- END -